Make Better Decisions

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Medtronic
Colorcon
Dow
Fuji
QuintilesIMS
Harvard Business School
Johnson and Johnson
Chubb
Teva

Generated: January 17, 2018

DrugPatentWatch Database Preview

Claims for Patent: 9,241,915

« Back to Dashboard

Summary for Patent: 9,241,915
Title:Method for enhancing the bioavailability of ospemifene
Abstract: This invention relates to a method for enhancing the bioavailability of a therapeutically active compound of the formula (I) ##STR00001## or a geometric isomer, a stereoisomer, a pharmaceutically acceptable salt, an ester thereof or a metabolite thereof, wherein said compound is administered orally to the individual in connection with the intake of food.
Inventor(s): Anttila; Markku (Turku, FI)
Assignee: QuatRx Pharmaceuticals (Ann Arbor, MI)
Application Number:14/310,822
Patent Claims: 1. A method for enhancing the bioavailability of a therapeutically active compound of the formula (I) ##STR00005## or a geometric isomer, a stereoisomer, a pharmaceutically acceptable salt, an ester thereof or a metabolite thereof, wherein said compound is administered orally to an individual in connection with the intake of food.

2. The method according to claim 1 wherein compound (I) is ospemifene.

3. The method according to claim 1 wherein the compound is administered at a time point which is in the range defined by 1 hour before starting the food intake and 2 hours after starting the food intake.

4. The method according to claim 3 wherein the compound is administered at a time point which is in the range defined to begin at a time point during the food intake and to end 1 hour after the food intake was started.

5. The method according to claim 4 wherein the compound is administered at a time point which is no later than 0.5 hour after starting the food intake.

6. The method according to claim 1 wherein the food is any foodstuff of nutritional value being capable of causing secretion of bile acids.

7. The method according to claim 1 wherein the compound is used for treatment of osteoporosis.

8. The method according to claim 1 wherein the compound is used for treatment of symptoms related to skin atrophy, or to epithelial or mucosal atrophy.

9. The method according to claim 8 wherein the symptoms are urinary symptoms or vaginal symptoms.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Fish and Richardson
Daiichi Sankyo
McKinsey
UBS
Medtronic
Healthtrust
Teva
Express Scripts
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot